
Golimumab - Psoriatic arthritis
You are here : Home > Formulary Search > Golimumab - Psoriatic arthritis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
Guidelines (Local)
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Golimumab
Indication :
Psoriatic arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Rheumatology,
Brand Names Include :
Simponi
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Golimumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Psoriatic arthritis.
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.